

OPEN ACCESS JOURNAL AT INIST-CNRS

Leukaemia Section

Short Communication

+4 or trisomy 4

Alessandro Beghini

Department of Biology and Genetics for Medical Sciences, Medical Faculty, University of Milan, Via Viotti 3/5, 20133 Milan, Italy (AB)

Published in Atlas Database: July 2000

Online updated version : http://AtlasGeneticsOncology.org/Anomalies/tri4ID1011.html DOI: 10.4267/2042/37648

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. © 2000 Atlas of Genetics and Cytogenetics in Oncology and Haematology

Clinics and pathology

Disease

Acute non lymphocytic leukaemia (ANLL)

Epidemiology

+4 as the sole anomaly is a rare chromosomal abnormality associated with a specific subtype of primary ANLL and secondary (treatment related) ANLL with myelomonocytic morphology; it has been found with the same frequence in the M1-M2 and M4 French-American-British (FAB) phenotypes.

Association of +4 with double minute chromosomes has been described in ten cases; five with AML-M2, two with AML-M4, one with refractory anemia with excess of blasts in transformation (RAEB-T), one with chronic myelomonocytic leukemia (CMMoL) and one with unclassified preleukemia.

The coincidence of +4 with t(8;21) or its variant t(6;21;8), observed in at least two cases of ANLL (M1 and M2), is therefore recurrent.

Prognosis

Apparently +4 has no prognostic significance in ANLL; with the exception of the cases bearing c-Kit mutations who are associated with a rapid disease progression.

Disease

Acute lymphocytic leukaemia (ALL)

Epidemiology

+4 has been described in two cases of T-cell acute lymphoblastic leukemia as the sole chromosomal anomaly.

Combined trisomies of chromosomes 4 and 10 are found in children with B-progenitor cell acute lymphoblastic leukemia with a favourable prognostic association.

Prognosis

Patients with chromosomes 4 and 10 trisomies have an extremely favourable 4-year event-free survival (EFS) after antimetabolite-based chemotherapy.

Disease

Thecoma of the ovary

Epidemiology

+4 associated with +12 has been described in two cases of fibrothecoma and in one case of thecoma; it has been suggested that acquisition of trisomy 4 may constitute a second cytogenetic step in tumor progression of ovarian thecoma/fibrothecoma.

Prognosis

No prognostic significance.

Disease

+4 has been found as the sole aberration only in one case of uterine leiomyoma.

Genetics

Note

Trisomy 4 was proven to lead to duplication of Asp816Tyr mutation of c-Kit gene (that maps to 4q12) in a case of M2-ANLL with mast cell involvement.

References

Mecucci C, Van Orshoven A, Tricot G, Michaux JL, Delannoy A, Van den Berghe H. Trisomy 4 identifies a subset of acute nonlymphocytic leukemias. Blood. 1986 May;67(5):1328-32

Harris MB, Shuster JJ, Carroll A, Look AT, Borowitz MJ, Crist WM, Nitschke R, Pullen J, Steuber CP, Land VJ. Trisomy of leukemic cell chromosomes 4 and 10 identifies children with B-progenitor cell acute lymphoblastic leukemia with a very low risk of treatment failure: a Pediatric Oncology Group study. Blood. 1992 Jun 15;79(12):3316-24

Mrózek K, Limon J, Debniak J, Emerich J. Trisomy 12 and 4 in a thecoma of the ovary. Gynecol Oncol. 1992 Apr;45(1):66-8

Kwong YL, Ha SY, Liu HW, Chan LC. Trisomy 4 may occur in a broad range of hematologic malignancies. Cancer Genet Cytogenet. 1993 Sep;69(2):139-40

Feuring-Buske M, Haase D, Könemann S, Troff C, Grove D, Hiddemann W, Wörmann B. Trisomy 4 in 'stem cell-like' leukemic cells of a patient with AML. Leukemia. 1995 Aug;9(8):1318-20

O'Malley F, Rayeroux K, Cole-Sinclair M, Tong M, Campbell LJ. MYC amplification in two further cases of acute myeloid

leukemia with trisomy 4 and double minute chromosomes. Cancer Genet Cytogenet. 1999 Mar;109(2):123-5

Beghini A, Ripamonti CB, Castorina P, Pezzetti L, Doneda L, Cairoli R, Morra E, Larizza L. Trisomy 4 leading to duplication of a mutated KIT allele in acute myeloid leukemia with mast cell involvement. Cancer Genet Cytogenet. 2000 May;119(1):26-31

This article should be referenced as such:

Beghini A. +4 or trisomy 4. Atlas Genet Cytogenet Oncol Haematol. 2000; 4(3):129-130.